Eli Lilly

YTD

ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.

CEO

David A. Ricks

CEODavid A. Ricks

Employees

47,000

Employees47,000

Headquarters

Indianapolis, Indiana

HeadquartersIndianapolis, Indiana

Founded

1876

Founded1876

Employees

47,000

Employees47,000

LLY Key Statistics

Market cap

808.80B

Market cap808.80B

Price-Earnings ratio

62.74

Price-Earnings ratio62.74

Dividend yield

0.73%

Dividend yield0.73%

Average volume

4.20M

Average volume4.20M

High today

$858.00

High today$858.00

Low today

$734.90

Low today$734.90

Open price

$840.80

Open price$840.80

Volume

8.10M

Volume8.10M

52 Week high

$972.53

52 Week high$972.53

52 Week low

$677.09

52 Week low$677.09

LLY News

Simply Wall St 55m

Eli Lilly Partners With BigHat And Achieves Phase 3 Success With Orforglipron

experienced a 2% decline last week, a movement that contrasts with a broader market drop of 3%. The company's share price was likely influenced by its strategic...

Benzinga 1h

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential

Eli Lilly And Co LLY on Thursday reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and in...

TipRanks 2h

Eli Lilly rises 14.1%

Eli Lilly (LLY) is up 14.1%, or $103.95 to $838.85. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try N...

Analyst ratings

90%

of 29 ratings

Buy

89.7%

Hold

10.3%

Sell

More LLY News

TipRanks 3h

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of o...

Quartz 3h

Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

The first GLP-1 pill could be in medicine cabinets sooner than expected. Eli Lilly (LLY) announced Thursday that its daily obesity pill, orforglipron, met comp...

Benzinga 4h

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday

U.S. stocks were lower, with the Dow Jones index falling around 550 points on Thursday. Shares of uniQure N.V. QURE rose sharply during Thursday's session afte...

Sherwood News 5h

Eli Lilly rises after weight-loss pill succeeds in trials

Eli Lilly rises after weight-loss pill succeeds in trials Eli Lilly’s once-daily weight-loss pill, orforglipron, succeeded in early trails with results similar...

TipRanks 6h

Eli Lilly Stock Goes Supersize after New Oral Weight Loss Drug Impresses in Trials

Shares in pharmaceuticals firm Eli Lilly (LLY) ballooned higher today after revealing its new needle-free weight loss drug had performed strongly in trials. Lo...

Benzinga 6h

Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars

Eli Lilly And Co LLY stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron c...

TipRanks 7h

Eli Lilly announces ACHIEVE-1 trial met primary endpoint

Eli Lilly (LLY) announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 d...